证券代码：002950 证券简称：奥美医疗 编号：2020-002 奥美医疗用品股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------|-----------------------------|----------------------------------------------------| | | | | | 投 资 者 关 系 活 | □ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | √ 其他 （分析师电话会议） | | | 参 与 单 位 名 称 | 详见附件《参会机构名单》 | | | 及人员姓名 | | | | 时间 | 2020 年 2 月 9 日 | | | 地点 | 电话会议 | | | 上 市 公 司 接 待 | | 董事、董事会秘书 杜先举；证券事务代表 郑晓程 | | 人员姓名 | | | | 投 资 者 关 系 活 | 1. | 能否介绍下公司口罩的供应情况。 | | 动 主 要 内 容 ...

证券代码：002950 证券简称：奥美医疗 奥美医疗用品股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------------|------------------------------------------------|------------------------------------------------------------------------------------|------------| | | | 编号： | 2021-001 | | 投 资 者关 系 活 | □ 特定对象调研 | □ 分析师会议 | | | 动类别 | □ 媒体采访 | √ 业绩说明会 | | | | □ 新闻发布会 | □ 路演活动 | | | | □ 现场参观 | | | | | □ 其他 （电话会议） | | | | 参 与 单位 名 称 及人员姓名 | 线上公众投资者 | | | | 时间 | 2021 年 5 月 11 日 | | | | 地点 | "奥美医疗投资者关系"微信小程序 | | | | 上 市 公司 接 待 | ...

证券代码：002950 证券简称：奥美医疗 奥美医疗用品股份有限公司投资者关系活动记录表 编号：2021-002 | --- | --- | --- | --- | |---------------|------------------------------------------------------|--------------------------------------------------|---------------| | | | | | | 投资者 关系活 | □ 特定对象调研 | □ 分析师会议 | | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | | □ 新闻发布会 | □ 路演活动 | | | | □ 现场参观 | | | | | √ 其他 湖北上市公司 2021 | 年度投资者网上集体接待日活动 | | | 参与单 位名称 | 线上公众投资者 | | | | 及人员姓名 | | | | | 时间 | 2021 年 6 月 24 日 | | | | 地点 | 全景网投资者关系互动平台 | | | | 上市公 司接待 | 董事、副总裁兼董事会秘书 | 杜先举；证券事 ...

股票代码：002950 股票简称：奥美医疗 奥美医疗用品股份有限公司投资者关系活动记录表 编号：2022-001 | --- | --- | --- | --- | |-----------------------|-----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|-------| | | | | | | 投资者关系活动类 | □ 特定对象调研 □ | 分析师会议 | | | 别 | □ 媒体采访 | √业绩说明会 | | | | □ 新闻发布会 □ | 路演活动 | | | | □ 现场参观 | | | | | □ 其他 | （请文字说明其他活动内容） | | | 参与单位名称及人 | 线上参与公司奥美医疗 | 2021 年度网上业绩说明会的投 | | | 员姓名 | 资者 | | | | 时间 | 202 ...

Revenue and Profitability - The company's revenue for Q3 2022 was ¥932,733,147, representing a 12.29% increase year-over-year, and a total revenue of ¥3,067,161,380.95 for the year-to-date, which is a 31.79% increase compared to the same period last year[3] - The net profit attributable to shareholders for Q3 2022 was a loss of ¥93,224,648.75, a decrease of 202.04% year-over-year, while the year-to-date net profit was ¥196,873,537.48, down 40.18% compared to the previous year[3] - Total operating revenue for the current period reached ¥3,067,161,380.95, a significant increase from ¥2,327,252,559.38 in the previous period, representing a growth of approximately 31.7%[16] - Net profit for the current period was ¥196,749,394.55, down from ¥330,867,284.85 in the previous period, reflecting a decrease of approximately 40.5%[17] - The total comprehensive income for the current period was ¥289,534,919.49, slightly down from ¥323,648,414.38 in the previous period, a decrease of about 10.5%[17] Cash Flow and Financial Position - The cash flow from operating activities for the year-to-date was ¥900,860,648.94, showing a significant increase of 275.58% compared to the same period last year[3] - The net cash flow from operating activities improved to ¥900,860,648.94, compared to ¥239,857,506.40 in the previous period, indicating a growth of about 274.5%[19] - The company reported a net cash outflow from investing activities of ¥1,067,174,157.15, compared to a net outflow of ¥941,221,354.73 in the previous period, indicating an increase in cash outflow of about 13.4%[19] - Net cash flow from financing activities was -236,928,160.88 CNY in Q3 2022, compared to -313,448,681.28 CNY in Q3 2021, indicating an improvement year-over-year[20] - The company reported a net decrease in cash and cash equivalents of -382,609,401.33 CNY for Q3 2022, compared to -1,013,433,841.51 CNY in Q3 2021, showing a significant reduction in cash burn[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,542,843,747.46, reflecting a 10.75% increase from the end of the previous year[3] - Total assets as of September 30, 2022, amounted to CNY 5,542,843,747.46, an increase from CNY 5,004,829,011.10 at the beginning of the year[13] - Total liabilities reached CNY 2,634,249,126.42, compared to CNY 2,252,783,574.08 at the beginning of the year[14] - The company's total equity attributable to shareholders at the end of the reporting period was ¥2,907,662,991.66, a 5.62% increase from the end of the previous year[3] - The company's total equity as of September 30, 2022, was CNY 2,908,594,621.04, up from CNY 2,752,045,437.02[14] Shareholder Information - The number of common shareholders at the end of the reporting period was 47,822[10] - The top shareholder, Cui Jinhai, holds 23.02% of the shares, totaling 145,794,859 shares[10] Expenses and Financial Performance - The company's basic and diluted earnings per share for Q3 2022 were both -¥0.1472, a decrease of 202.04% year-over-year[3] - The company's research and development expenses decreased by 21.46% year-over-year to ¥45,635,755.64[8] - The financial expenses increased significantly by 1636.59% year-over-year to ¥199,980,941.51, primarily due to exchange losses from the depreciation of the RMB against the USD[8] - The company experienced a loss in investment income of ¥9,128,577.84, contrasting with a gain of ¥23,145,832.72 in the previous period[16] - Basic earnings per share decreased to ¥0.3109 from ¥0.5197, reflecting a decline of approximately 40%[17]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately CNY 2.13 billion, representing a 42.62% increase compared to CNY 1.50 billion in the same period last year [29]. - The net profit attributable to shareholders for the first half of 2022 was approximately CNY 290.10 million, a 22.01% increase from CNY 237.77 million in the previous year [29]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately CNY 307.22 million, reflecting a significant increase of 55.47% compared to CNY 197.61 million in the same period last year [29]. - The net cash flow from operating activities reached approximately CNY 559.15 million, a remarkable increase of 698.05% from CNY 70.06 million in the previous year [29]. - The total assets at the end of the reporting period were approximately CNY 5.66 billion, up 13.07% from CNY 5.00 billion at the end of the previous year [29]. - The net assets attributable to shareholders at the end of the reporting period were approximately CNY 2.95 billion, an increase of 7.12% from CNY 2.75 billion at the end of the previous year [29]. - The company reported a basic earnings per share of CNY 0.4581, which is a 22.00% increase compared to CNY 0.3755 in the same period last year [29]. - The weighted average return on equity for the reporting period was 10.01%, an increase of 2.46% from 7.55% in the previous year [29]. Market Strategy and Expansion - The company plans to enhance its market presence in emerging markets such as the Middle East and Africa, as well as expand its domestic medical supplies market share [6]. - The company aims to strengthen its partnerships with key international medical device brands to secure stable revenue streams [6]. - The company is focused on the medical dressing market, which is expected to grow due to increasing demands for wound healing and comfort from patients [38]. - The company is positioned to capitalize on the growing demand for high-quality medical dressings in both domestic and international markets [43]. - The company aims to expand its product line by adding high-value consumables based on existing products like Vaseline gauze [46]. - The company has developed a series of new products tailored to different market needs, including sterile care packages for medical institutions and a range of personal protective products for the retail market [69]. Risk Management - The company has implemented strategies to mitigate risks associated with raw material price fluctuations, including centralized procurement and local sourcing to manage costs effectively [8]. - The company is exposed to foreign exchange risks due to its foreign currency-denominated sales, and it has adopted measures such as careful currency selection and the use of financial instruments to hedge against these risks [9]. - The company has established a professional derivatives trading team to manage risks related to raw material procurement and currency fluctuations [11]. - The company emphasizes the importance of maintaining a robust internal control system for its derivative transactions to mitigate trading risks [11]. - The company has implemented a comprehensive risk management system for foreign exchange derivative transactions, ensuring no speculative operations are conducted [110]. Product Development and Innovation - The company is committed to ongoing research and development of new products and technologies to enhance its competitive edge in the medical supplies market [6]. - The company has developed a comprehensive range of wound care solutions, including non-stick wound pads and various types of gauze [47]. - The surgical consumables segment includes innovative products like X-ray detectable gauze and non-woven surgical drapes [50]. - The company has invested in R&D and innovation, resulting in multiple software copyrights and patents, maintaining its competitive edge in the medical dressing sector [77]. - The company aims to continue focusing on market demand and core technologies to create tailored product solutions for different scenarios [70]. Corporate Governance and Financial Management - The company will not distribute cash dividends or issue bonus shares, indicating a focus on reinvestment [12]. - The company has implemented a comprehensive quality management system, adhering to international standards such as ISO13485 and FDA regulations, which has strengthened customer confidence [76]. - The company has no significant changes in asset measurement attributes during the reporting period [93]. - The company has not reported any significant litigation or arbitration matters during the reporting period [132]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period [137]. Social Responsibility and Community Engagement - In response to the COVID-19 pandemic, the company donated over 2 million RMB worth of medical supplies to various regions, including 500,000 RMB worth of supplies to Shenzhen [120]. - The company supplied over 40 million masks and 100,000 bottles of hand sanitizer to Shanghai during the peak of the outbreak from March to April 2022 [123]. - The company donated nearly 4.78 million surgical masks valued at approximately 2 million RMB to support high school students and staff during the 2022 examination period [124]. - The company provided 200,000 KN95 masks and medical protective masks valued at 450,000 RMB to the Hong Kong Federation of Trade Unions to assist in combating COVID-19 [121]. - The company arranged for 17.5 containers of supplies to support Shanghai's epidemic prevention efforts [123]. Financial Position and Assets - The company's total assets increased to CNY 4,235,642,730.72, compared to CNY 4,147,088,396.72 at the end of the first half of 2021 [181]. - The company's total liabilities increased to RMB 2,709,319,506.74 as of June 30, 2022, up from RMB 2,252,783,574.08, indicating a rise of approximately 20.2% [177]. - The company's equity attributable to shareholders rose to RMB 2,948,899,521.84 from RMB 2,752,953,286.33, marking an increase of about 7.1% [177]. - The company's inventory stood at RMB 853,700,859.44 as of June 30, 2022, slightly up from RMB 846,628,943.74 at the beginning of the year [175]. - The company's accounts receivable rose to RMB 502,029,260.61 from RMB 425,145,128.23, an increase of about 18.1% [175].

奥美医疗用品股份有限公司 2022 年第一季度报告全文 证券代码：002950 证券简称：奥美医疗 公告编号：2022-017 奥美医疗用品股份有限公司 2022 年第一季度报告 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 □ 适用 √ 不适用 (二)非经常性损益项目和金额 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 √ 适用 □ 不适用 单位：元 将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益项 目的情况说明 1 □ 适用 √ 不适用 奥美医疗用品股份有限 ...

Financial Performance - The company's operating revenue for 2021 was CNY 2,925,554,887.71, a decrease of 23.70% compared to CNY 3,834,498,022.40 in 2020 [28]. - The net profit attributable to shareholders for 2021 was CNY 431,214,849.37, down 62.75% from CNY 1,157,526,566.11 in the previous year [28]. - The net profit after deducting non-recurring gains and losses was CNY 343,185,202.57, a decline of 67.66% compared to CNY 1,061,118,748.22 in 2020 [28]. - The net cash flow from operating activities was CNY 374,852,202.76, a significant drop of 73.91% from CNY 1,436,740,713.51 in the previous year [28]. - Basic earnings per share decreased to CNY 0.68, down 62.84% from CNY 1.83 in 2020 [28]. - Total assets at the end of 2021 were CNY 5,004,829,011.10, an increase of 3.06% from CNY 4,856,080,464.92 at the end of 2020 [28]. - The net assets attributable to shareholders decreased to CNY 2,752,953,286.33, down 5.42% from CNY 2,910,700,528.82 at the end of 2020 [28]. - The company reported a weighted average return on equity of 15.65%, a decrease of 28.35% from 44.00% in 2020 [28]. - The company achieved total operating revenue of CNY 292,555.49 million, a decrease of 23.70% year-on-year, and a net profit attributable to shareholders of CNY 43,121.48 million, down 62.75% year-on-year [82]. - The company's overseas operating revenue was CNY 233,586.22 million, accounting for 79.84% of total revenue, while domestic revenue was CNY 58,969.27 million, representing 20.16% of total revenue, with a year-on-year decline of 50.92% [84]. - The proportion of pandemic-related revenue in total revenue decreased to 14.82% in 2021 from 39.92% in 2020, indicating a more balanced revenue structure [85]. Market Strategy and Expansion - The company is expanding into emerging markets in the Middle East, Asia, Africa, and Latin America to mitigate risks associated with concentrated overseas markets [7]. - The company is focused on increasing its market share in domestic medical supplies and infection protection markets [7]. - The company aims to leverage its unique manufacturing capabilities to expand its market presence and explore potential mergers and acquisitions for growth [53]. - The company is actively expanding its domestic market share through various channels, including e-commerce, OTC markets, and hospital partnerships, with products now available in over 70,000 pharmacies [88]. - The company is focused on building advanced production capacity and integrating automation and information technology into its manufacturing processes [93]. - The company plans to enhance supply chain management and expand product categories in response to domestic procurement policies and UDI regulations, leveraging its experience in overseas GPO participation [138]. Product Development and Innovation - The company is positioned as a leading player in the domestic medical dressing industry, focusing on product innovation and process upgrades [50]. - The company continues to expand its low-value consumables product line, providing a one-stop product supply service to meet various usage scenarios [53]. - The company is extending its product line into high-value consumables based on high-margin products like petroleum jelly gauze, creating a multi-tiered product offering [53]. - The company has launched a series of consumer products in the respiratory protection, wound care, and daily care categories, leveraging over 20 years of experience in textile and medical products [60]. - The company has developed various new products, including medical cold compresses and oral rinses, expanding its product portfolio [68]. - The company plans to develop high-end medical dressings, including silicone foam dressings and hydrocolloid dressings, to expand its market presence [111]. Risk Management - The company faces risks from high reliance on export revenue, which is influenced by international market conditions and currency fluctuations [7]. - The company emphasizes the importance of foreign exchange risk management and employs various financial tools to control potential risks [9]. - The company has established a professional team for derivative trading to ensure effective risk management and compliance with internal controls [11]. - The company utilizes derivative instruments like cotton futures and forward foreign exchange contracts to hedge against price volatility and currency risks [10]. - The company has established a risk management system for its foreign exchange derivative products, ensuring compliance with relevant laws and regulations [132]. Corporate Governance - The company has implemented a robust governance structure, complying with relevant laws and regulations to enhance transparency and investor relations [146]. - The company has established an independent financial department with a standardized accounting system and independent bank accounts, ensuring complete control over financial decisions [156]. - The company has a clear ownership of all assets, including production facilities, trademarks, and patents, with no asset occupation by controlling shareholders [156]. - The board of directors includes experienced professionals, with the chairman and president, Cui Jinhai, having held the position since September 2016 [162]. - The company has maintained a stable governance structure with independent directors and supervisors since its establishment [162]. Social Responsibility and Community Engagement - The company actively responded to the COVID-19 pandemic by establishing a special supply group to ensure the production and delivery of medical supplies, including N95 masks and protective clothing, to various regions in need [192]. - In 2021, the company donated over 3 million RMB worth of medical supplies to support flood relief efforts in Henan province following severe flooding [192]. - The company received recognition from the Hubei Charity Federation for its contributions to disaster relief efforts during the floods [195]. - The company was awarded the title of "Most Growth-Oriented Listed Company in the Health Industry" and "Most Socially Responsible Listed Company" in the 2021 China Listed Company Reputation Rankings [197]. - The company has a commitment to employee welfare, having been recognized as a "Harmonious Enterprise" by the Hubei Provincial Human Resources and Social Security Department [198]. Employee Management and Development - The total number of employees at the end of the reporting period was 4,964, including 3,871 at the parent company and 1,093 at major subsidiaries [175]. - The company has established a training system focused on strategic talent development to enhance overall employee quality and management capabilities [177]. - The professional composition included 3,881 production personnel, 52 sales personnel, 411 technical personnel, 34 financial personnel, and 586 administrative personnel [175]. - The company has a performance-based compensation policy that aligns with organizational and individual performance assessments [165]. - The company is committed to regularly reviewing its compensation and incentive systems to ensure competitiveness [165].

Financial Performance - The company's revenue for Q3 2021 was ¥830,658,090.81, a decrease of 0.31% compared to the same period last year, and a year-to-date revenue of ¥2,327,252,559.38, down 24.65% year-on-year [4]. - Net profit attributable to shareholders for Q3 2021 was ¥91,362,715.90, a decline of 63.09%, with a year-to-date net profit of ¥329,132,304.17, down 65.69% [4]. - The basic earnings per share for Q3 2021 was ¥0.1443, reflecting a decrease of 63.09% compared to the same period last year [4]. - Total operating revenue for the current period is $2,327,252,559.38, down from $3,088,744,908.97 in the previous period, representing a decrease of approximately 24.6% [20]. - Net profit for the current period is $330,867,284.85, a decline of 65.5% compared to $960,718,427.09 in the same period last year [21]. - Basic earnings per share decreased to $0.5197 from $1.5146, reflecting a drop of approximately 65.7% [22]. - The total comprehensive income for the current period is $323,648,414.38, down from $942,347,156.76 in the previous period, a decrease of about 65.6% [22]. Assets and Liabilities - The company's total assets at the end of Q3 2021 were ¥4,878,627,077.32, an increase of 0.46% from the end of the previous year [5]. - Current assets decreased to CNY 2,211,661,598.31 from CNY 2,836,267,822.98, representing a decline of approximately 22% [16]. - Total liabilities increased to CNY 2,209,997,979.88 from CNY 1,932,969,618.30, marking an increase of approximately 14% [18]. - Total equity decreased to CNY 2,668,629,097.44 from CNY 2,923,110,846.62, a decline of approximately 9% [18]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥239,857,506.40, down 79.31% compared to the same period last year [4]. - Cash flow from operating activities generated a net amount of $239,857,506.40, significantly lower than $1,159,186,199.55 in the previous period [25]. - In Q3 2021, the net cash flow from financing activities was -313,448,681.28 CNY, compared to a positive 328,114,054.69 CNY in the same period last year [26]. - Total cash and cash equivalents at the end of Q3 2021 were 288,406,450.62 CNY, down from 837,610,741.62 CNY at the end of Q3 2020 [26]. Investments and Expenses - Research and development expenses increased by 17.82% to ¥58,101,424.18, indicating a focus on innovation [10]. - The company reported a significant increase in long-term equity investments by 88.36% to ¥741,452,100.48, reflecting increased external investments [10]. - The company experienced a 77.85% decrease in cash and cash equivalents, totaling ¥288,406,450.62, primarily due to profit distribution and increased investments [10]. - Cash inflow from investment activities totaled $1,948,559,246.47, compared to $1,442,324,531.71 in the previous period, indicating an increase of about 35.2% [25]. - Cash outflow from investment activities increased to $2,889,780,601.20 from $2,328,805,064.68, representing a rise of approximately 24% [25]. Shareholder Information - The number of common shareholders at the end of the reporting period was 51,122 [13]. - The company received government subsidies amounting to ¥68,463,898.47, an increase of 77.56% compared to the previous year [10]. Other Information - The company did not undergo an audit for the Q3 2021 report [27]. - The new leasing standards were not applicable for the financial statements in 2021 [27].

Revenue and Financial Performance - The company reported significant revenue growth in its main business areas, including wound care and infection prevention, largely driven by increased overseas sales due to the pandemic [7]. - The company's operating revenue for the first half of 2021 was ¥1,496,594,468.57, a decrease of 33.65% compared to ¥2,255,525,258.33 in the same period last year [23]. - The net profit attributable to shareholders was ¥237,769,588.27, down 66.59% from ¥711,645,802.44 in the previous year [23]. - The net cash flow from operating activities was ¥70,064,884.14, reflecting a significant decline of 91.73% compared to ¥847,505,458.58 in the same period last year [23]. - The basic earnings per share decreased to ¥0.3755, down 66.59% from ¥1.1238 in the previous year [23]. - The company's total revenue for the current period is ¥1,496,594,468.57, representing a decrease of 33.65% compared to ¥2,255,525,258.33 in the same period last year [86]. - The company's pandemic-related revenue accounted for only 14.71% of total revenue in the first half of 2021, indicating strong risk resistance compared to industry peers [69]. - In the first half of 2021, the company achieved total revenue of CNY 1,496,594,468.57, a decrease of 33.65% year-on-year, while net profit attributable to shareholders was CNY 237,769,588.27, down 66.59% year-on-year [67]. Market Expansion and Strategy - The company plans to expand its market presence in emerging markets such as the Middle East and Africa, aiming to reduce reliance on concentrated overseas markets [3]. - The company aims to increase its market share in the domestic medical supplies sector to diversify its revenue sources [3]. - The company is focusing on expanding its market presence in the global medical dressing outsourcing sector, which has seen significant growth due to increased production outsourcing in developed countries [37]. - The company is expanding into emerging markets in the Middle East, Asia, Africa, and Latin America to mitigate risks associated with overseas market concentration [107]. Product Development and Innovation - The company is focused on optimizing its product line and accelerating the construction of its disease control and protection product manufacturing base [7]. - The company emphasizes the importance of product innovation and development in response to the growing demand for advanced wound healing solutions driven by an aging population [37]. - The company has developed a variety of new products, such as the OB pads designed for postpartum use, which feature high absorbency and hygiene protection [35]. - New product developments include high-efficiency medical masks that have already been launched in the market [81]. - The company is committed to providing high-quality products and services, with a focus on long-term demand and competitive pricing in the post-pandemic era [69]. Financial Management and Risk Control - The company has implemented a dual procurement strategy for raw materials, combining centralized purchasing for bulk commodities and localized sourcing to mitigate cost fluctuations [4]. - The company is actively enhancing its foreign exchange risk management practices, including the use of forward contracts and options to hedge against currency fluctuations [4]. - The company has established a robust internal control system for derivative trading to manage risks associated with commodity price volatility and foreign exchange rates [5]. - The company is implementing risk control measures for its derivative investments, focusing on hedging against currency and interest rate fluctuations [104]. - The company faces risks from high reliance on foreign sales, which are influenced by export policies, currency exchange rates, and international market fluctuations [107]. Research and Development - R&D expenses for the first half of 2021 amounted to ¥39,780,603.49, representing a 36.46% increase year-on-year [78]. - The company acquired a 55% stake in Wuhan Baima Biotechnology Co., enhancing its R&D capabilities in biopolymer materials [80]. - The company holds 196 patents as of August 20, 2021, an increase of 111 patents year-on-year, reflecting a 115.6% growth [79]. - The company has focused on R&D innovation, investing in automation and smart management systems, resulting in several software copyrights [60]. Environmental and Social Responsibility - The company has implemented a comprehensive wastewater treatment process, ensuring that discharge concentrations meet the required standards [122]. - The total discharge of COD is 88.468 tons per year, with a concentration of 203.9928 mg/L, which is compliant with the standards [122]. - The company actively responds to national environmental protection policies and conducts self-inspections [122]. - The company has passed multiple social responsibility audits during the reporting period [125]. Shareholder and Equity Information - The total number of shares before the change was 633,265,407, with a post-change total of 633,265,407, indicating no overall change in total shares [156]. - The largest shareholder, Cui Jinhai, holds 145,794,859 shares, representing 23.02% of total shares [160]. - The company has not reported any share repurchase or reduction activities during the reporting period [157]. - The total approved external guarantees during the reporting period amounted to CNY 337,435.05 million, with actual guarantees totaling CNY 60,428.8 million [149].